Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 18/20 | 0.61 |
| ▸ | SELP | P16109 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15488911 | 0.95 | SELE (0.62) | SELESELP | |
| SCHEMBL13295107 | 0.95 | SELE (0.61) | SELESELP | |
| SCHEMBL13657266 | 0.93 | SELE (0.65) | SELESELP | |
| SCHEMBL15214014 | 0.92 | SELE (0.65) | SELESELP | |
| SCHEMBL14823276 | 0.92 | SELE (0.71) | SELESELP | |
| SCHEMBL19559698 | 0.92 | SELE (0.66) | SELESELP | |
| SCHEMBL16257570 | 0.88 | SELE (0.69) | SELESELP | |
| SCHEMBL12240052 | 0.87 | SELE (0.52) | SELESELP | |
| SCHEMBL14823286 | 0.87 | SELE (0.64) | SELESELP | |
| SCHEMBL13040187 | 0.87 | SELE (0.54) | SELESELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2264043-B1 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | GLYCOMIMETICS INC (US) | 2015-02-19 | — | — | US | disclosed |
| US-8895510-B2 | Pan-selectin inhibitor with enhanced pharmacokinetic activity | GLYCOMIMETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | GLYCOMIMETICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8633303-B2 | Heterobifunctional pan-selectin inhibitors | GLYCOMIMETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | GLYCOMIMETICS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361332-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
| US-20070054870-A1 | glycomimetics; selectin binding modulators for use in treatment ofinflammatory, autoimmune, infection, cancer, shock, thrombosis, wounds, burns, reperfusion injury, blood, leukocyte-mediated lung injury, spinal cord damage, digestive tract mucous membrane disorders, osteoporosis, arthritis and asthma | BSG, SELE, SELL | SELE 2/4885SELP 6/4885 |
| US-20150051164-A1 | PAN-SELECTIN INHIBITOR WITH ENHANCED PHARMACOKINETIC ACTIVITY | SELPLG, SELP, SELE | SELE 3/4885SELP 2/4885 |
| US-20140178303-A1 | HETEROBIFUNCTIONAL PAN-SELECTIN INHIBITORS | SELE, SELP, BSG | SELE 1/4885SELP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.